Features | Partner Sites | Information | LinkXpress
Sign In
FOCUS DIAGNOSTICS, INC.
RANDOX LABORATORIES
Bio-Rad Diabetes Division

Multigene Assay Predicts Cancer Patient's Survival

By Labmedica International staff writers
Posted on 19 Aug 2014
Image: Histopathology of clear cell renal cell carcinoma (Photo courtesy of Nephron).
Image: Histopathology of clear cell renal cell carcinoma (Photo courtesy of Nephron).
Patients with clear cell renal cell carcinoma (ccRCC) have divergent survival outcomes and therapeutic responses, which may be determined by underlying molecular diversity.

A practical molecular assay has been developed that can identify subtypes with differential prognosis and response to targeted therapy and predict treatment and survival outcomes in kidney cancer patients.

Scientists at the Institute of Bioengineering and Nanotechnology (Republic of Singapore) and their colleagues conducted a retrospective study with a cohort of 279 ccRCC patients who underwent surgery at Singapore General Hospital (Republic of Singapore) between 1999 and 2012. They developed a practical expression-based assay with utility in formalin-fixed paraffin-embedded (FFPE) material that assigns biologic subtypes of ccRCC, characterized by differential prognosis and treatment response.

Ribonucleic acid (RNA) was extracted from a set of 55 FFPE samples (SGH-55) and processed for whole-genome expression analysis by Whole Genome (WG)-DASL (Illumina; San Diego, CA, USA). Quantitative polymerase chain reaction (qPCR) assays were designed for measuring expression in FFPE tissue; expression data for potential prognostic and normalization genes for SGH-55 were collected. A model assigning prognostic subtype was developed based on the combination of qPCR expression values of eight genes: chemokine (C-X-C motif) ligand 5 (CXCL5), ephrin A5 (EFNA5), endomucin (EMCN), laminin beta3 (LAMB3), plasminogen (PLG), preferentially expressed antigen in melanoma (PRAME), retinoic acid receptor responder (tazarotene induced) 1 (RARRES1), and solute carrier family 6 (neutral amino acid transporter), member 19 (SLC6A19).

Min-Han Tan, MBBS, PhD, the senior author of the study, said, “Our diagnostic assay successfully classified ccRCC into groups that correlated to different survival and treatment outcomes. This allows patients and doctors to make more educated choices in their treatment options. Outcomes can be very different. Some patients can be observed for years on end, some benefit from immediate treatment including surgery or targeted therapy, and for some patients, treatment can be futile. Experience is required in making the right judgment for patients. We hope our assay will play a role in helping that judgment.” The study was published on July 10, 2014, in the journal European Urology.

Related Links:

Institute of Bioengineering and Nanotechnology
Singapore General Hospital 
Illumina



77 ELEKTRONIKA
DiagCor Bioscience
PURITAN MEDICAL
comments powered by Disqus
Life Technologies

Channels

Clinical Chemistry

view channel
Image:  The Agilent 6890 GC with 5973 Mass Spectrometer and Tekmar Velocity XPT Purge & Trap (Photo courtesy of Gen Tech).

Low Levels of Prohormone Predicts Coronary Heart Disease

The adrenal sex hormone dehydroepiandrosterone (DHEA), which is present in serum mainly as the sulfate DHEA-S, is the most abundant steroid hormone in human blood and its levels decline dramatically with age.... Read more

Microbiology

view channel
Image: The causative parasite of Chagas disease Trypanosoma cruzi in a blood film (Photo courtesy of the CDC - US Centers for Disease Control and Prevention).

Undiagnosed Chagas Disease Emerging as Public Health Threat

Chagas disease or American trypanosomiasis is typically spread to people through the feces of blood-sucking triatomine bugs sometimes called kissing bugs because they feed on people's faces during the night.... Read more

Pathology

view channel
Image: The Isolation by Size of Epithelial Tumor cells (ISET) technology (Photo courtesy of Rarecells Diagnostics).

Circulating Tumor Cells Allow Early Diagnosis of Lung Cancer

Chronic obstructive pulmonary disease (COPD) is a risk factor for lung cancer and migration of circulating tumor cells (CTCs) into the blood stream is an early event that occurs during carcinogenesis.... Read more

Industry News

view channel

Oncology Companion Diagnostics Sector Grows to Over USD 1 Billion

The market for diagnostic test and pharmaceutical drug pairs for cancer treatment has grown significantly, according to the report “Companion Diagnostic Markets” from healthcare market research firm Kalorama Information (New York City, NY, USA). The global companion diagnostics (CDx) market is valued at about USD 1.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.